
SOTS 2nd Hour: Novo Nordisk Oral Weight-Loss Pill, Global Market Outlook, “Aggressive Housing Reform” 12/23/25
Squawk on the Street
00:00
Efficacy Edge and Competitive Positioning
Novo's CEO highlights 17% weight-loss efficacy parity with injectables and how that sustains competitive advantage.
Play episode from 20:47
Transcript


